Loading...

FATE FATE THERAPEUTICS INC Operational Disruptions 8-K Filing

FT T

FT

FATE THERAPEUTICS INC

(FATE)

2024 8-K

Show Summary

Show Summary

Financial Statements

Financial Results

Management Changes

Management Changes

Financial Results

Indemnification Agreement

Financial Results

Board Increase and Appointm...

Amendment Approval

Appointment of CFO

Resignation and Appointment

Financial Results Announcement

Phase 1 Study Results

Equity Offering

Financial Results Announcement

Registration Statement and ...

Earnings Reports

Litigation Update

Earnings Report

Annual Meeting Results

Resignation of CMO

Presentation at Jefferies H...

Earnings Reports

Amendment to Certificate of...

Financial Results Announcement

Termination of Collaboratio...

External Links:

Fate Therapeutics announced the treatment of the first patient in its Phase 1 autoimmunity study of FT819 and presented translational data from its Phase 1 study of FT819 and FT522 at the ASGCT 27th Annual Meeting.

AI Assistant

FATE THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.